Table 2.
Indication for ERCP.
| CBD stone | 159 (60.7) |
| Malignancies | 61 (23.3) |
| Cholangiocarcinoma | 27 (44.3) |
| Gall bladder cancer | 14 (23.0) |
| Pancreatic cancer | 11 (18.0) |
| AoV cancer | 5 (8.2) |
| HCC | 4 (6.6) |
| Benign structure | 23 (8.8) |
| Others | 19 (7.3) |
| SOD | 5 (26.3) |
| Pancreatic pseudocyst | 4 (21.1) |
| IPMN | 3 (15.8) |
| Post cholecystectomy biliary leakage | 3 (15.8) |
| Choledochal cyst | 1 (5.3) |
| PSC | 1 (5.3) |
| Pancreatic NET | 1 (5.3) |
| AoV adenoma | 1 (5.3) |
ERCP, endoscopic retrograde cholangiography; CBD, common bile duct; AoV, ampulla of Vater; SOD, sphincter of Oddi dysfunction; IPMN, intrapapillary mucinous neoplasm; PSC, primary sclerosing cholangitis; NET, neuroendocrine tumor.